This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Invest in Stryker (SYK) Right Now
by Zacks Equity Research
Stryker (SYK) gains from stellar performance of the flagship Mako platform; guidance solid.
Express Scripts (ESRX) to Launch Pilot Program, Shares Up
by Zacks Equity Research
Express Scripts (ESRX) aims to add value to patients' diagnosis in return for higher costs.
Pacific Biosciences Gains as HudsonAlpha Picks Sequel System
by Zacks Equity Research
Pacific Biosciences (PACB) sees increasing use of Sequel Sequencing System in pediatric and plant biologic case studies.
Masimo Gets CE Mark for NomoLine, Expands in Capnography
by Zacks Equity Research
Masimo (MASI) upgrades respiratory monitoring through the newly-approved Rad-97 Pulse Co-Oximeter with integrated capnography sampling lines.
Here's Why You Should Hold on to Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab (ECL) gains on core segmental business, while intense competition raises concern.
Texas Hospital Administers Cerner's (CERN) Millenium System
by Zacks Equity Research
Cerner's (CERN) EHR will provide comprehensive care to RHCD and improve patient engagement through a new online portal.
Here's Why You Should Invest in Fresenius Medical Right Now
by Zacks Equity Research
Fresenius Medical (FMS) receives a boost from solid guidance, higher geographical revenues and strategic acquisitions.
Why Is Envision Healthcare Corporation (EVHC) Up 4.57% Since Its Last Earnings Report?
by Zacks Equity Research
EVHC reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Is Envision Healthcare (EVHC) a Great Stock for Value Investors?
by Zacks Equity Research
Envision Healthcare (EVHC) appears to be a good choice for value investors right now, given its favorable P/E and P/S metrics.
5 Reasons Why Centene is an Attractive Bet for Investors
by Zacks Equity Research
Centene (CNC) can be considered a lucrative investment option on the back of top-line growth, inorganic strategies and a solid financial health.
Envision Healthcare Divests AMR Unit, Streamlines Business
by Zacks Equity Research
Envision Healthcare (EVHC) divests its American Medical Response business to reduce leverage and focus on high-growth business.
Why BioScrip (BIOS) Could Be Positioned for a Slump
by Zacks Equity Research
BioScrip (BIOS) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Envision Healthcare (EVHC) Q4 Earnings Beat, Revenues Rise
by Zacks Equity Research
Envision Healthcare (EVHC) earnings benefited from higher revenues partly offset by an increase in expenses.
Can Revenue Rise Aid Envision Healthcare (EVHC) Q4 Earnings?
by Zacks Equity Research
Envision Healthcare (EVHC) Q4 earnings might see an upside from higher revenues in Physician Services segment, partly offset by high expenses and lower revenues from Ambulatory Service segment.
Is a Surprise Coming for Envision Healthcare (EVHC) This Earnings Season?
by Zacks Equity Research
Envision Healthcare (EVHC) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Will Higher Revenues Buoy Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) fourth-quarter 2017 results to benefit from an increase in members utilizing its services, higher visits and growing client roaster.
Zacks.com featured highlights include: Sonic Automotive, Target, Envision Healthcare, Beazer Homes and Group 1
by Zacks Equity Research
Zacks.com featured highlights include: Sonic Automotive, Target, Envision Healthcare, Beazer Homes and Group 1
5 Stocks in the Limelight on Recent Broker Rating Upgrades
by Zacks Equity Research
Proper guidance from brokers is all the more necessary now as the Q4 earnings season is just round the corner. Investors would look to add potential out performers to their respective portfolios.
Will Envision Healthcare's Growth Strategies Help the Stock?
by Zacks Equity Research
Envision Healthcare (EVHC) is expected to gain from is a number of long term growth strategies.
4 Reasons Why Envision Healthcare (EVHC) Looks Dull
by Zacks Equity Research
Envision Healthcare continues to suffer from low patient volumes, increased leverage, high operating expense and a weak operating environment.
Envision Healthcare Down More Than 50% This Year, Here's Why
by Zacks Equity Research
Envision Healthcare (EVHC) seems to be bogged down by soft patient volumes, increasing expenses and high leverage.
Implied Volatility Surging for Envision Healthcare (EVHC) Stock Options
by Zacks Equity Research
Envision Healthcare (EVHC) needs investors to pay close attention to the stock based on moves in the options market lately.
Why Envision Healthcare (EVHC) Could Be Positioned for a Slump
by Zacks Equity Research
Envision Healthcare (EVHC) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Envision Healthcare Hits 52-Week Low on Q3 Miss, Grim View (Revised)
by Zacks Equity Research
Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.
Envision Healthcare Hits 52-Week Low on Q3 Loss, Grim View
by Zacks Equity Research
Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.